Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furaprevir + Imateprevir phosphate + ribavirin in chronic HCV genotype 1
CTR20190878Phase 3Completed
- Sponsor
- Dongguan Dongyangguang Taijing Pharmaceutical Research and Development
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furaprevir, yimitasvir, ribavirin in hepatitis C virus infection, sponsored by Dongguan Dongyangguang Taijing Pharmaceutical Research and Development. Started Jun 2019; status: completed.
02
Drugs
furapreviryimitasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20190878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190878.